CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade X4 Pharmaceuticals, Inc. - XFOR CFD

1.01
0.98%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.05
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003929%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

X4 Pharmaceuticals Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 1.02
Open* 1.03
1-Year Change* 9.57%
Day's Range* 1.01 - 1.05
52 wk Range 0.65-2.58
Average Volume (10 days) 1.23M
Average Volume (3 months) 60.60M
Market Cap 208.00M
P/E Ratio -100.00K
Shares Outstanding 164.43M
Revenue N/A
EPS -1.05
Dividend (Yield %) N/A
Beta 0.72
Next Earnings Date Nov 1, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Sep 21, 2023 1.02 0.02 2.00% 1.00 1.06 0.98
Sep 20, 2023 1.01 -0.03 -2.88% 1.04 1.08 1.00
Sep 19, 2023 1.06 0.01 0.95% 1.05 1.07 1.03
Sep 18, 2023 1.06 -0.01 -0.93% 1.07 1.10 1.03
Sep 15, 2023 1.08 -0.08 -6.90% 1.16 1.18 1.06
Sep 14, 2023 1.18 0.01 0.85% 1.17 1.19 1.11
Sep 13, 2023 1.18 0.02 1.72% 1.16 1.21 1.13
Sep 12, 2023 1.15 -0.05 -4.17% 1.20 1.21 1.15
Sep 11, 2023 1.22 0.02 1.67% 1.20 1.22 1.16
Sep 8, 2023 1.20 -0.02 -1.64% 1.22 1.24 1.20
Sep 7, 2023 1.24 -0.01 -0.80% 1.25 1.26 1.20
Sep 6, 2023 1.26 -0.03 -2.33% 1.29 1.29 1.19
Sep 5, 2023 1.27 -0.03 -2.31% 1.30 1.30 1.23
Sep 1, 2023 1.27 0.01 0.79% 1.26 1.29 1.25
Aug 31, 2023 1.26 -0.03 -2.33% 1.29 1.31 1.25
Aug 30, 2023 1.31 0.03 2.34% 1.28 1.31 1.24
Aug 29, 2023 1.28 0.00 0.00% 1.28 1.31 1.26
Aug 28, 2023 1.27 -0.01 -0.78% 1.28 1.31 1.24
Aug 25, 2023 1.28 0.06 4.92% 1.22 1.30 1.22
Aug 24, 2023 1.24 -0.04 -3.13% 1.28 1.33 1.21

X4 Pharmaceuticals, Inc. Events

Time (UTC) Country Event
Wednesday, November 1, 2023

Time (UTC)

12:30

Country

US

Event

Q3 2023 X4 Pharmaceuticals Inc Earnings Release
Q3 2023 X4 Pharmaceuticals Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 0 0 3 0 3.5
Total Operating Expense 87.569 85.107 63.036 52.269 49.385
Selling/General/Admin. Expenses, Total 27.02 24.702 20.942 16.64 18.406
Research & Development 61.058 50.647 41.932 30.163 30.979
Unusual Expense (Income) -0.509 9.758 0.162 5.466 0
Operating Income -87.569 -85.107 -60.036 -52.269 -45.885
Interest Income (Expense), Net Non-Operating -2.073 -3.998 -2.852 -0.767 -0.23
Other, Net -4.197 0.426 0.905 0.229 3.094
Net Income Before Taxes -93.839 -88.679 -61.983 -52.807 -43.021
Net Income After Taxes -93.867 -88.696 -62.131 -52.807 -43.021
Net Income Before Extra. Items -93.867 -88.696 -62.131 -52.807 -43.021
Net Income -93.867 -88.696 -62.131 -52.807 -43.021
Total Adjustments to Net Income -2.546 -13.943 0 -0.592 0
Income Available to Common Excl. Extra. Items -96.413 -102.639 -62.131 -53.399 -43.021
Income Available to Common Incl. Extra. Items -96.413 -102.639 -62.131 -53.399 -43.021
Dilution Adjustment
Diluted Net Income -96.413 -102.639 -62.131 -53.399 -43.021
Diluted Weighted Average Shares 63.526 25.749 20.077 11.53 2.38466
Diluted EPS Excluding Extraordinary Items -1.51769 -3.98614 -3.09464 -4.63131 -18.0408
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS -1.5229 -3.73981 -3.08939 -4.15724 -16.573
Revenue 0 0 3 3.5
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0 0 0 0 0
Revenue
Total Operating Expense 25.805 29.304 25.577 20.154 20.57
Selling/General/Admin. Expenses, Total 10.204 7.241 6.563 6.044 6.749
Research & Development 15.601 22.063 19.014 14.11 13.821
Unusual Expense (Income) 0 0 0 0 0
Operating Income -25.805 -29.304 -25.577 -20.154 -20.57
Interest Income (Expense), Net Non-Operating -0.234 -0.274 0.244 -1.004 -0.579
Other, Net -29.658 5.562 -3.757 -0.441 -0.059
Net Income Before Taxes -55.697 -24.016 -29.09 -21.599 -21.208
Net Income After Taxes -55.712 -24.02 -29.104 -21.586 -21.212
Net Income Before Extra. Items -55.712 -24.02 -29.104 -21.586 -21.212
Net Income -55.712 -24.02 -29.104 -21.586 -21.212
Total Adjustments to Net Income 0 0 0 -0.287 0
Income Available to Common Excl. Extra. Items -55.712 -24.02 -29.104 -21.873 -21.212
Income Available to Common Incl. Extra. Items -55.712 -24.02 -29.104 -21.873 -21.212
Diluted Net Income -55.712 -24.02 -29.104 -21.873 -21.212
Diluted Weighted Average Shares 168.738 145.967 101.176 83.211 35.437
Diluted EPS Excluding Extraordinary Items -0.33017 -0.16456 -0.28766 -0.26286 -0.59858
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.33017 -0.16456 -0.28766 -0.26286 -0.59858
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 128.677 87.878 83.307 129.278 35.08
Cash and Short Term Investments 121.718 81.787 78.708 126.184 30.754
Cash 0.918
Total Receivables, Net 1.152 0.747 0.917 1.998 2.859
Prepaid Expenses 5.522 5.344 3.418 1.096 1.007
Other Current Assets, Total 0.285 0 0.264 0.46
Total Assets 155.586 117.176 122.871 160.698 36.004
Property/Plant/Equipment, Total - Net 8.333 10.224 9.197 2.362 0.285
Property/Plant/Equipment, Total - Gross 9.561 10.948 9.471 2.626 2.556
Accumulated Depreciation, Total -1.228 -0.724 -0.274 -0.264 -2.271
Other Long Term Assets, Total 1.225 1.723 3.258 1.949 0.639
Total Current Liabilities 22.324 14.023 11.948 9.447 5.398
Accounts Payable 7.777 4.283 3.144 2.088 0.545
Accrued Expenses 13.232 8.945 8.804 7.359 4.116
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 1.315 0.795 0 0
Other Current Liabilities, Total 0.737
Total Liabilities 81.535 52.764 50.072 31.478 14.404
Total Long Term Debt 32.304 33.139 33.178 20.097 7.894
Long Term Debt 32.304 33.139 33.178 20.097 7.894
Other Liabilities, Total 26.907 5.602 4.946 1.934 1.112
Total Equity 74.051 64.412 72.799 129.22 21.6
Redeemable Preferred Stock 0
Common Stock 0.122 0.028 0.016 0.016 0.015
Additional Paid-In Capital 450.786 347.374 267.077 261.367 156.63
Retained Earnings (Accumulated Deficit) -376.738 -282.871 -194.175 -132.044 -135.286
Other Equity, Total -0.119 -0.119 -0.119 -0.119 0.241
Total Liabilities & Shareholders’ Equity 155.586 117.176 122.871 160.698 36.004
Total Common Shares Outstanding 121.667 28.1277 16.3057 16.1289 2.42871
Cash & Equivalents 121.718 81.787 78.708 126.184 29.836
Goodwill, Net 17.351 17.351 27.109 27.109
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total Current Assets 98.222 128.677 85.718 52.585 70.881
Cash and Short Term Investments 93.406 121.718 79.855 47.378 66.427
Cash & Equivalents 93.406 121.718 79.855 47.378 66.427
Total Receivables, Net 0.658 1.152 0.909 0.843 0.868
Prepaid Expenses 3.908 5.807 4.954 4.364 3.586
Total Assets 124.405 155.586 113.406 81.019 99.625
Property/Plant/Equipment, Total - Net 7.83 8.333 8.8 9.285 9.747
Property/Plant/Equipment, Total - Gross 9.185 9.561 9.904 10.265 10.604
Accumulated Depreciation, Total -1.355 -1.228 -1.104 -0.98 -0.857
Goodwill, Net 17.351 17.351 17.351 17.351 17.351
Other Long Term Assets, Total 1.002 1.225 1.537 1.798 1.646
Total Current Liabilities 19.483 22.324 28.713 22.002 14.97
Accounts Payable 5.992 7.777 3.8 3.677 3.569
Accrued Expenses 12.937 13.232 10.292 9.718 7.986
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 72.729 81.535 51.557 50.946 49.911
Total Long Term Debt 31.827 32.304 18.733 24.49 29.809
Long Term Debt 31.827 32.304 18.733 24.49 29.809
Other Liabilities, Total 21.419 26.907 4.111 4.454 5.132
Total Equity 51.676 74.051 61.849 30.073 49.714
Common Stock 0.122 0.122 0.069 0.031 0.031
Additional Paid-In Capital 452.431 450.786 409.533 356.209 354.638
Retained Earnings (Accumulated Deficit) -400.758 -376.738 -347.634 -326.048 -304.836
Other Equity, Total -0.119 -0.119 -0.119 -0.119 -0.119
Total Liabilities & Shareholders’ Equity 124.405 155.586 113.406 81.019 99.625
Total Common Shares Outstanding 122.207 121.667 68.7346 30.9912 30.8095
Current Port. of LT Debt/Capital Leases 0.554 1.315 14.621 8.607 3.415
Other Current Assets, Total 0.25
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -93.867 -88.696 -62.131 -52.807 -43.021
Cash From Operating Activities -77.102 -70.905 -58.818 -48.055 -40.903
Cash From Operating Activities 0.513 0.499 0.351 0.103 0.155
Non-Cash Items 10.516 18.79 7.025 7.885 6.424
Changes in Working Capital 5.736 -1.498 -4.063 -3.236 -4.461
Cash From Investing Activities -0.103 -0.615 -1.362 27.232 -0.034
Capital Expenditures -0.103 -0.615 -1.362 -0.174 -0.034
Cash From Financing Activities 117.23 74.245 12.394 140.661 -4.531
Financing Cash Flow Items -4.814 0 -0.278 -0.043
Issuance (Retirement) of Stock, Net 122.839 74.245 0.284 140.18 0.179
Issuance (Retirement) of Debt, Net -0.795 0 12.388 0.481 -4.667
Foreign Exchange Effects -0.105 -0.319 0.402 -0.25 -0.286
Net Change in Cash 39.92 2.406 -47.384 119.588 -45.754
Cash Interest Paid 3.006 2.906 2.099 1.284
Other Investing Cash Flow Items, Total 0 0 27.406
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -24.02 -93.867 -64.763 -43.177 -21.965
Cash From Operating Activities -26.512 -77.102 -58.009 -38.703 -20.229
Cash From Operating Activities 0.127 0.513 0.389 0.265 0.133
Non-Cash Items -3.235 10.516 6.104 3.818 1.903
Changes in Working Capital 0.616 5.736 0.261 0.391 -0.3
Cash From Investing Activities -0.009 -0.103 -0.069 -0.06 -0.022
Capital Expenditures -0.009 -0.103 -0.069 -0.06 -0.022
Cash From Financing Activities -2.124 117.23 56.586 4.609 4.956
Issuance (Retirement) of Stock, Net -0.443 122.839 60.693 5.855 5.877
Issuance (Retirement) of Debt, Net -1.681 -0.795 -0.795 -1.234 -0.909
Foreign Exchange Effects 0.05 -0.105 -0.468 -0.271 -0.069
Net Change in Cash -28.595 39.92 -1.96 -34.425 -15.364
Financing Cash Flow Items 0 -4.814 -3.312 -0.012 -0.012
Cash Interest Paid 3.006
Other Investing Cash Flow Items, Total

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

X4 Pharmaceuticals, Inc. Company profile

About X4 Pharmaceuticals Inc

X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of therapeutics for the treatment of rare diseases with an initial focus on the treatment of people with immune system dysfunction. Its lead product candidate, mavorixafor, is a small molecule inhibitor of the chemokine receptor CXCR4 and is being developed as a once-daily oral therapy. Its mavorixafor demonstrated ability to antagonize CXCR4 and improve the healthy maturation and trafficking of white blood cells (WBCs), which provides therapeutic benefit across a variety of diseases, including primary immunodeficiencies (PIDs) and certain types of cancer. Its mavorixafor is in a global Phase III clinical trial for the treatment of warts, hypogammaglobulinemia, infections and myelokathexis (WHIM) syndrome, a rare, inherited PID caused by genetic mutations in the CXCR4 receptor gene. Its product candidates include X4P-001, X4P-002 and X4P-003.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, X4 Pharmaceuticals Inc revenues decreased from $3M to $0K. Net loss applicable to common stockholders increased 65% to $102.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 21% to $47.9M (expense).

Industry: Biotechnology & Medical Research (NEC)

61 North Beacon Street
4th Floor
BOSTON
MASSACHUSETTS 02134
US

Income Statement

  • Annual
  • Quarterly

News

EUR/USD tests key support

EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

14:32, 21 September 2023
Bank of England building

BoE leaves rates unchanged, GBP drops further as investors look for more clarity

The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

11:45, 21 September 2023
British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

GBP softer after CPI surprise, JPY focused on any further hints from Ueda

GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

12:42, 20 September 2023

How to Trade The Break & Retest

In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

11:59, 20 September 2023

Cable coils near lows ahead of Fed and BoE rate decisions

It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.

14:16, 19 September 2023

FTSE 100 Technical Outlook - 18 September 2023

In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.

06:55, 19 September 2023
View of the City of London’s illuminated financial district skyline at dusk

Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally

The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.

13:46, 15 September 2023

People also watch

BTC/USD

26,625.25 Price
-0.030% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 85.00

Oil - Crude

90.14 Price
+0.770% 1D Chg, %
Long position overnight fee 0.0415%
Short position overnight fee -0.0634%
Overnight fee time 21:00 (UTC)
Spread 0.030

XRP/USD

0.52 Price
+0.700% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01192

ETH/USD

1,598.51 Price
+0.560% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 5.40

Still looking for a broker you can trust?

Join the 555.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading